🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#TumorBoardTuesday 🤷Who would have ever imagined that there would be TOO many options to consider for advanced liver cancer‼️ 📢Join us Tuesday, 10-01-24 at 8PM ET as Ghassan Abou-Alfa & Layal Al Mahmasani🗣️Advanced #HCC Treatment in the IO Era RT and bring others into the discussion‼️

It's time! #TumorBoardTuesday is back with a very interesting case. How do we think about doublet IO vs VEGF + IO in #HCC? With boards around the corner, I'll be paying attention (and hoping the❓have caught up with all the recent changes in practice)! Follow along 👇!

#TumorBoardTuesday Ghassan Abou-Alfa Integrity CE, LLC Memorial Sloan Kettering Cancer Center MSK Department of Medicine 16/24 Five-year analysis of HIMALAYA 📢Sustained OS benefit with STRIDE vs sorafenib 📢5-year OS rates 19.6% with STRIDE vs 9.4% with sorafenib Ghassan Abou-Alfa

More on this from the Sabin Vaccine Institute, a non-profit working on developing vaccines for high-consequence diseases in low- and middle-income countries. Truly a mind-blowing achievement and an exemplar for future outbreak response.

#TumorBoardTuesday Wungki Park, MD MS Journal of Clinical Oncology @JonathanOstrem Kevan Shokat Rona Yaeger NEJM Tanios Bekaii-Saab, MD Nature Medicine 16/24 Early P1 data from RMC-6236, a RAS-on inhibitor targeting multiple mutant alleles, shows response signal across KRAS variants in patients who have received multiple prior lines of treatment 🤩 📰P3 RCT vs chemo is coming! bit.ly/3Ue65uD

#TumorBoardTuesday G Curigliano MD PhD 12/20 #TumorBoardTuesday 👩🏻‍🏫Mini tweetorial 6👨🏻‍🏫 📌What is HER2 ultralow? 🔹 Faint, incomplete staining in ≤10% tumor cells 🔹 20-25% of HR+/HER2- mBC are HER2 ultralow 🚨 repeat biopsy to broaden eligibility to TDXd

#TumorBoardTuesday 👏It is amazing how many HER2🎯💊options there are for metastatic bladder cancer 📢Join us Tuesday, 10-29-24 at 8PM ET as Matt Galsky & Eric Miller, MD 🗣️the multitude of therapies for HER2+ Bladder Cancer RT and bring others into the discussion‼️

#TumorBoardTuesday Matt Galsky 1/27 #TumorBoardTuesday #OncTwitter Your patient presents for follow up: 68 year old 👨 with no significant PMH except urothelial cancer 📖  Previously treated with cystectomy ➡️ adjuvant gem/cis ‼️ Metastatic nodal recurrence detected via ctDNA and PET after 6 months

What is the role of HER2 directed therapy in #HER2+ #urothelialcancer? Not something I think of right away- but with the approval of T-DXd for IHC 3+ in ANY site, how do we think about this? Join in w #TumorBoardTuesday live! 👇

Thoracic #TumorBoardTuesday during Lung Cancer Awareness Month? An easy YES!! Join Kelsey Pan, MD, MPH & I this week as we discuss the ever-evolving 1L treatment landscape of metastatic EGFR+ NSCLC! 📅 11/12/24 ⏰ 8-9 PM ET #lcsm #lcam #lungcancerawarenessmonth

#TumorBoardTuesday In this holiday season, I am so ready to spend an hour smiling😀laughing😆and learning🧑🏼‍🎓for our next session 📢Join us Tuesday, 12-10-24 at 8PM ET as Balazs Halmos & Angelica D'Aiello, MD🗣️periOp mgmt of resectable #NSCLC RT and bring others into the discussion‼️

Great pleasure to re-introduce Angelica D'Aiello, MD to #lcsm in new role tonite- previous #TumorBoardTuesday ctDNA session champion- Montefiore Health System resident➡️fellow➡️chief fellow➡️now brand new Albert Einstein College of Medicine - Official med onc faculty! She also just had a baby a few months ago BUT i am told thoracic onc

#TumorBoardTuesday Balazs Halmos Integrity CE, LLC Roy Herbst NEJM 3/29 #TumorBoardTuesday 👩‍🏫Mini tweetorial 2👨‍🏫 🚨ADAURA Results 💊Adjuvant osimertinib vs placebo ⭐️5 yr OS 88% vs 78% (HR 0.49, p <0.001) ⭐️DFS 65.8 mo vs 28.1 mo 🏆Adj osimertinib is now FDA approved/SOC

#TumorBoardTuesday Balazs Halmos Integrity CE, LLC Roy Herbst NEJM 5/29 #TumorBoardTuesday 👩‍🏫Mini tweetorial 4 👨‍🏫 👉PACIFIC regimen = SOC for Stage IIIB NSCLC 🧐No OS benefit for EGFRm subset.. 💁‍♀️LAURA ⭐️Phase III - osi after chemoRT ⭐️Unresectable stage III EGFRm NSCLC 👏Osi vs placebo➡️med PFS 39.1 vs 5.6 mo 🏆Osi after chemoRT = new SOC

#TumorBoardTuesday David S. Hong MD george demetri Journal of Clinical Oncology Colorectal Cancer Canada @elena_elez Arvind Dasari, MD, MS 17/20 #TumorBoardTuesday Clinical trials/ICI in MSS colon cancer, particularly without liver mets showing encouraging ph 1 data: 🔶Rego/nivo/ipi pmc.ncbi.nlm.nih.gov/articles/pmid/… 🔶BOT/BAL nature.com/articles/s4159… Consider enrolling in clinical trial if available CCTG

Johnathan Ebben MD, PhD Cynthia #TumorBoardTuesday David S. Hong MD george demetri Journal of Clinical Oncology #TumorBoardTuesday 👉This is what Nathan A. Pennell MD, PhD, FASCO taught us years ago in #NSCLC 💵It is much more cost effective just to order a whole🧬panel

#GI25🎤drop #NEST🪺🙋🏻‍♂️🙌🏽 |➖➖➖➖➖➖➖➖➖➖ 💯 | | | | | | | | |————————————————— ✅NO RECURRENCES📅! 💡Neoadjuvant immunotherapy keeps delivering! 👉🏽Patients with MSS🧊NOT just MSI-High🔥colorectal #cancer. Goal is to👏🏾*CURE*👏🏾more patients. 🔜Phase2/3 OncoAlert ASCO

20/20 #TumorBoardTuesday Summary Ability to detect oligomets will likely change with more use of PET-PSMA, e.g., patients with biochemical relapse but no apparent mets on conventional CT or bone scan → 74% PSMA-positive lesions

#TumorBoardTuesday 📢With all the advances in the Tx of met #breastcancer, how about options for Pts w/ #brainmetastases 🧠 ❓ Join us Tuesday, 03-18-25 at 8 pm ET as Dr Sarah Sammons and Ilana Schlam 🗣️a patient with mBC and🧠metastases RT and bring others into the discussion‼️

#TumorBoardTuesday Did you all recover from #ASCO25 ❓😀 Ready for more learning❓🧑‍🏫 📢Join us Tuesday, 06-17-25 at 8PM ET as Eric K. Singhi, MD & Kelsey Pan, MD, MPH 🗣️Targeting🎯classical EGFR mutations in metastatic #NSCLC RT and bring others into the discussion‼️